BACKGROUND: Granulocyte colony-stimulating factor mobilized peripheral blood stem cells are increasingly used instead of bone marrow as a stem cell source for transplantation. Whereas this change is almost complete for autologous transplantation, there are some concerns when considering allogeneic transplants. DESIGN AND METHODS: We performed a retrospective case-control study including 820 adult patients who had received an allogeneic stem cell transplant from an HLA-identical sibling donor. Quality of life (QoL) was assessed in 150 patients using the EORTC Quality of Life Questionnaire C30 (QLQ-C30). RESULTS: There were no statistically significant differences in overall survival at ten years (bone marrow: 48.9% vs. peripheral blood stem cells: 39.8%; p=0.621), transplant-related mortality (bone marrow: 28.9% vs. peripheral blood stem cells: 34.4%; p=0.682) or relapse incidence at 9 years (29.4% vs. 35.2%, respectively; p=0.688). Similar outcomes were maintained independently of the phase of the disease. However, multivariate analysis identified a higher incidence of acute graft-versus-host disease grades II-IV (p: 0.023; Hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.05-1.89) and grades III-IV (p: 0.006; HR: 1.89; 95% CI: 1.20-2.98), in the peripheral blood stem cells-stem cell transplant group. As previously described, extensive chronic graft-versus-host disease was also more frequent in the peripheral blood stem cells group (28% vs. 15.6%; p<0.001). Patients transplanted with peripheral blood stem cells had significant impairment of role and social functioning. CONCLUSIONS: Although overall survival was not affected by the stem cell source, peripheral blood stem cell transplants were associated with a higher risk of both acute and chronic GvHD. Global quality of life was similar in both groups, but patients transplanted with peripheral blood stem cells showed worse role and social functioning scores, probably related to the increased incidence of chronic graft-versus-host disease.
BACKGROUND: Granulocyte colony-stimulating factor mobilized peripheral blood stem cells are increasingly used instead of bone marrow as a stem cell source for transplantation. Whereas this change is almost complete for autologous transplantation, there are some concerns when considering allogeneic transplants. DESIGN AND METHODS: We performed a retrospective case-control study including 820 adult patients who had received an allogeneic stem cell transplant from an HLA-identical sibling donor. Quality of life (QoL) was assessed in 150 patients using the EORTC Quality of Life Questionnaire C30 (QLQ-C30). RESULTS: There were no statistically significant differences in overall survival at ten years (bone marrow: 48.9% vs. peripheral blood stem cells: 39.8%; p=0.621), transplant-related mortality (bone marrow: 28.9% vs. peripheral blood stem cells: 34.4%; p=0.682) or relapse incidence at 9 years (29.4% vs. 35.2%, respectively; p=0.688). Similar outcomes were maintained independently of the phase of the disease. However, multivariate analysis identified a higher incidence of acute graft-versus-host disease grades II-IV (p: 0.023; Hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.05-1.89) and grades III-IV (p: 0.006; HR: 1.89; 95% CI: 1.20-2.98), in the peripheral blood stem cells-stem cell transplant group. As previously described, extensive chronic graft-versus-host disease was also more frequent in the peripheral blood stem cells group (28% vs. 15.6%; p<0.001). Patients transplanted with peripheral blood stem cells had significant impairment of role and social functioning. CONCLUSIONS: Although overall survival was not affected by the stem cell source, peripheral blood stem cell transplants were associated with a higher risk of both acute and chronic GvHD. Global quality of life was similar in both groups, but patients transplanted with peripheral blood stem cells showed worse role and social functioning scores, probably related to the increased incidence of chronic graft-versus-host disease.
Authors: Stephen Couban; David R Simpson; Michael J Barnett; Christopher Bredeson; Lothar Hubesch; Kang Howson-Jan; Tsiporah B Shore; Irwin R Walker; Peter Browett; Hans A Messner; Tony Panzarella; Jeffrey H Lipton Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: O Ringdén; M Labopin; A Bacigalupo; W Arcese; U W Schaefer; R Willemze; H Koc; D Bunjes; E Gluckman; V Rocha; A Schattenberg; F Frassoni Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: N Worel; D Biener; P Kalhs; M Mitterbauer; F Keil; A Schulenburg; P Höcker; K Dieckmann; G Fischer; A Rosenmayr; W Linkesch; W Hinterberger; K Lechner; H T Greinix Journal: Bone Marrow Transplant Date: 2002-11 Impact factor: 5.483
Authors: Philippe Guardiola; Volker Runde; Andrea Bacigalupo; Tapani Ruutu; Franco Locatelli; Marc A Boogaerts; Antonio Pagliuca; Jan J Cornelissen; Harry C Schouten; Enric Carreras; Jürgen Finke; Anja van Biezen; Ronald Brand; Dietger Niederwieser; Eliane Gluckman; Theo M de Witte Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: R E Champlin; N Schmitz; M M Horowitz; B Chapuis; R Chopra; J J Cornelissen; R P Gale; J M Goldman; F R Loberiza; B Hertenstein; J P Klein; E Montserrat; M J Zhang; O Ringdén; S C Tomany; P A Rowlings; M E Van Hoef; A Gratwohl Journal: Blood Date: 2000-06-15 Impact factor: 22.113
Authors: Norbert Schmitz; Meral Beksac; Dirk Hasenclever; Andrea Bacigalupo; Tapani Ruutu; Arnon Nagler; Eliane Gluckman; Nigel Russell; Jane F Apperley; Norbert C Gorin; Jeff Szer; Ken Bradstock; Agnes Buzyn; Peter Clark; Keith Borkett; Alois Gratwohl Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: A Gratwohl; H Baldomero; K Frauendorfer; V Rocha; J Apperley; D Niederwieser Journal: Bone Marrow Transplant Date: 2007-12-17 Impact factor: 5.483
Authors: Heather S L Jim; Bryan Evans; Jiyeon M Jeong; Brian D Gonzalez; Laura Johnston; Ashley M Nelson; Shelli Kesler; Kristin M Phillips; Anna Barata; Joseph Pidala; Oxana Palesh Journal: Biol Blood Marrow Transplant Date: 2014-04-18 Impact factor: 5.742
Authors: Marie T Rubio; Bipin N Savani; Myriam Labopin; Simona Piemontese; Emmanuelle Polge; Fabio Ciceri; Andrea Bacigalupo; William Arcese; Yener Koc; Dietrich Beelen; Zafer Gülbas; Depei Wu; Stella Santarone; Johanna Tischer; Boris Afanasyev; Christoph Schmid; Sebastian Giebel; Mohamad Mohty; Arnon Nagler Journal: J Hematol Oncol Date: 2016-03-15 Impact factor: 17.388